On March 18th, the FDA published draft guidance on validating new approach methodologies (NAMs), including complex in vitro models (CIVMs).
To continue reading click here
On March 18th, the FDA published draft guidance on validating new approach methodologies (NAMs), including complex in vitro models (CIVMs).
To continue reading click here
